ABL1 and leukemia: Minimal residual disease (MRD) after the induction phase is typically monitored by high-sensitivity methods, which detect leukemic cells at a frequency of 1 × 10−4 or lower, such as flow cytometry analysis of leukemia-specific surface markers or qPCR to identify leukemia-specific BCR-ABL1 transcripts.